MX389759B - ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTOEGENESIS IMPERFECTA (OI). - Google Patents

ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTOEGENESIS IMPERFECTA (OI).

Info

Publication number
MX389759B
MX389759B MX2019009122A MX2019009122A MX389759B MX 389759 B MX389759 B MX 389759B MX 2019009122 A MX2019009122 A MX 2019009122A MX 2019009122 A MX2019009122 A MX 2019009122A MX 389759 B MX389759 B MX 389759B
Authority
MX
Mexico
Prior art keywords
imperfecta
ostoegenesis
tgfß
antibodies
fragments
Prior art date
Application number
MX2019009122A
Other languages
English (en)
Other versions
MX2019009122A (es
Inventor
Brendan Lee
Kuber T Sampath
Original Assignee
Baylor College Medicine
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50483613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX389759(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baylor College Medicine, Genzyme Corp filed Critical Baylor College Medicine
Publication of MX2019009122A publication Critical patent/MX2019009122A/es
Publication of MX389759B publication Critical patent/MX389759B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona métodos para tratar y mejorar los síntomas de la osteogénesis imperfecta (OI) en un sujeto administrando al sujeto una cantidad terapéuticamente eficaz de un agente de unión que se une a factor de crecimiento transformante beta (TGFß).
MX2019009122A 2013-03-20 2014-03-20 ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTOEGENESIS IMPERFECTA (OI). MX389759B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361803647P 2013-03-20 2013-03-20
US201361875399P 2013-09-09 2013-09-09
US201361883151P 2013-09-26 2013-09-26
PCT/US2014/031279 WO2014153435A1 (en) 2013-03-20 2014-03-20 Methods for treating osteogenesis imperfecta

Publications (2)

Publication Number Publication Date
MX2019009122A MX2019009122A (es) 2019-09-16
MX389759B true MX389759B (es) 2025-03-20

Family

ID=50483613

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015013402A MX369360B (es) 2013-03-20 2014-03-20 ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTEOGÉNESIS IMPERFECTA (0I).
MX2019009122A MX389759B (es) 2013-03-20 2014-03-20 ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTOEGENESIS IMPERFECTA (OI).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015013402A MX369360B (es) 2013-03-20 2014-03-20 ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTEOGÉNESIS IMPERFECTA (0I).

Country Status (26)

Country Link
US (4) US9598486B2 (es)
EP (3) EP2976359B2 (es)
JP (3) JP6483086B2 (es)
KR (1) KR102257138B1 (es)
CN (2) CN105229028B (es)
AU (1) AU2014235933B2 (es)
CA (1) CA2907422C (es)
CL (1) CL2015002801A1 (es)
DK (2) DK2976359T4 (es)
EA (1) EA032327B1 (es)
ES (2) ES2763869T3 (es)
HR (2) HRP20181939T4 (es)
HU (1) HUE046702T2 (es)
IL (2) IL241461B (es)
LT (2) LT2976359T (es)
MX (2) MX369360B (es)
MY (1) MY172324A (es)
PH (2) PH12015501864A1 (es)
PL (2) PL3312195T3 (es)
PT (2) PT2976359T (es)
RS (2) RS59673B1 (es)
SG (2) SG11201506683XA (es)
SI (2) SI3312195T1 (es)
TW (1) TWI629995B (es)
UY (1) UY35493A (es)
WO (1) WO2014153435A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9598486B2 (en) * 2013-03-20 2017-03-21 Genzyme Corporation Methods for treating osteogenesis imperfecta
TWI733661B (zh) * 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
WO2018027329A1 (en) * 2016-08-11 2018-02-15 Precithera, Inc. TGF-β ANTAGONIST CONJUGATES
CN106755395B (zh) * 2016-12-16 2020-05-12 山东第一医科大学(山东省医学科学院) Xi型成骨不全致病基因fkbp10的突变位点及其应用
EP3571227A1 (en) * 2017-01-20 2019-11-27 Sanofi Anti-tgf-beta antibodies and their use
TWI856437B (zh) * 2017-01-20 2024-09-21 法商賽諾菲公司 抗TGF-β抗體及其用途
AR110904A1 (es) * 2017-01-20 2019-05-15 Sanofi Sa ANTICUERPOS ANTI-TGF-b Y SU USO
TW202421659A (zh) * 2017-01-20 2024-06-01 美商健臻公司 骨靶向抗體
US20190248881A1 (en) * 2017-12-04 2019-08-15 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
CN112703038B (zh) 2018-07-10 2025-07-29 赛诺菲 靶向CD38和TGF-β的抗癌组合疗法
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN110916855A (zh) * 2018-09-20 2020-03-27 天津正天医疗器械有限公司 一种仿生多孔椎间植入物及其制造方法
CN116744959A (zh) * 2020-10-23 2023-09-12 韩汇泉 肿瘤坏死因子-α和转化生长因子-β的双功能拮抗剂及其用途
IL308175A (en) * 2021-05-07 2023-12-01 Baylor College Medicine Treatment of moderate to severe defective bone formation
CN113501879B (zh) * 2021-06-30 2022-09-06 拜盖特生物科技(上海)有限公司 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法
TW202334209A (zh) * 2021-11-01 2023-09-01 美商健臻公司 成骨不全症之治療
AU2024207355A1 (en) * 2023-01-13 2025-08-21 Chimagen Biosciences, Ltd Multi-specific polypeptide complexes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6716836A (es) * 1967-12-11 1969-06-13
US7368111B2 (en) * 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU1525700A (en) * 1998-11-19 2000-06-05 Board Of Trustees Of The University Of Arkansas, The Increasing bone strength with selected bisphosphonates
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6395511B1 (en) * 1998-11-27 2002-05-28 Darwin Discovery, Ltd. Nucleic acids encoding a novel family of TGF-β binding proteins from humans
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
CA2308532C (en) * 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
EP1850873B1 (en) 2005-02-08 2018-11-28 Genzyme Corporation Antibodies to tgfbeta
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
JP2009521496A (ja) * 2005-12-23 2009-06-04 イーライ リリー アンド カンパニー ＴＧＦ−β結合組成物
WO2008022182A1 (en) * 2006-08-16 2008-02-21 The Uab Research Foundation Methods for promoting coupling between bone formation and resorption
KR20200054317A (ko) 2007-02-09 2020-05-19 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
JP2010528586A (ja) * 2007-04-26 2010-08-26 プレジデント アンド フェローズ オブ ハーバード カレッジ 骨形成及び鉱化作用を調節する化合物の同定のためのアッセイ
AR068767A1 (es) * 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
WO2009091905A1 (en) 2008-01-15 2009-07-23 Kalobios Pharmaceuticals, Inc. Methods of treating bone-loss disorders using a gm-csf antagonist
ES2702049T3 (es) * 2009-04-24 2019-02-27 Univ Vanderbilt Inducción anti-TGF-beta de crecimiento óseo
US9598486B2 (en) * 2013-03-20 2017-03-21 Genzyme Corporation Methods for treating osteogenesis imperfecta

Also Published As

Publication number Publication date
CN111000997A (zh) 2020-04-14
UY35493A (es) 2014-11-28
CN105229028A (zh) 2016-01-06
US20160031979A1 (en) 2016-02-04
SI2976359T1 (sl) 2019-03-29
MX2019009122A (es) 2019-09-16
ES2763869T3 (es) 2020-06-01
US20170247439A1 (en) 2017-08-31
JP6677837B2 (ja) 2020-04-08
TW201524515A (zh) 2015-07-01
SG10201701985YA (en) 2017-04-27
CN105229028B (zh) 2019-11-08
ES2700238T5 (es) 2022-05-20
HRP20181939T4 (hr) 2022-05-13
SG11201506683XA (en) 2015-09-29
LT2976359T (lt) 2018-12-27
HK1213576A1 (en) 2016-07-08
HRP20192277T1 (hr) 2020-03-06
WO2014153435A1 (en) 2014-09-25
PH12015501864B1 (en) 2015-12-07
PL3312195T3 (pl) 2020-04-30
KR20150132262A (ko) 2015-11-25
EP3312195B1 (en) 2019-10-09
US10377819B2 (en) 2019-08-13
US11230595B2 (en) 2022-01-25
IL241461A0 (en) 2015-11-30
DK3312195T3 (da) 2020-01-06
US20190389943A1 (en) 2019-12-26
IL287915A (en) 2022-01-01
JP6483086B2 (ja) 2019-03-13
SI2976359T2 (sl) 2022-05-31
JP2016519093A (ja) 2016-06-30
RS58188B2 (sr) 2022-06-30
KR102257138B1 (ko) 2021-05-26
EA032327B1 (ru) 2019-05-31
EA201591843A1 (ru) 2016-01-29
AU2014235933A1 (en) 2015-10-01
CA2907422C (en) 2021-08-31
CL2015002801A1 (es) 2016-08-12
RS59673B1 (sr) 2020-01-31
PH12019500261B1 (en) 2021-03-26
MX2015013402A (es) 2016-01-08
AU2014235933B2 (en) 2019-01-24
US12365725B2 (en) 2025-07-22
EP2976359B2 (en) 2022-03-23
DK2976359T3 (da) 2019-01-02
PH12015501864A1 (en) 2015-12-07
EP2976359A1 (en) 2016-01-27
IL241461B (en) 2021-12-01
US9598486B2 (en) 2017-03-21
DK2976359T4 (da) 2022-06-13
MX369360B (es) 2019-11-06
CA2907422A1 (en) 2014-09-25
PL2976359T3 (pl) 2019-03-29
EP2976359B1 (en) 2018-08-29
US20220195025A1 (en) 2022-06-23
PT2976359T (pt) 2018-12-05
HUE046702T2 (hu) 2020-03-30
PH12019500261A1 (en) 2020-07-20
NZ712353A (en) 2021-04-30
PL2976359T5 (pl) 2022-07-18
LT3312195T (lt) 2020-01-10
EP3640260A1 (en) 2020-04-22
JP2020109110A (ja) 2020-07-16
ES2700238T3 (es) 2019-02-14
EP3312195A1 (en) 2018-04-25
JP2019089826A (ja) 2019-06-13
JP7016113B2 (ja) 2022-02-04
PT3312195T (pt) 2019-12-23
MY172324A (en) 2019-11-21
RS58188B1 (sr) 2019-03-29
HRP20181939T1 (hr) 2019-01-25
SI3312195T1 (sl) 2020-02-28
HK1253717A1 (en) 2019-06-28
BR112015023905A2 (pt) 2017-10-24
TWI629995B (zh) 2018-07-21

Similar Documents

Publication Publication Date Title
MX389759B (es) ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTOEGENESIS IMPERFECTA (OI).
MX2016005050A (es) Uso de moleculas de union a semaforina-4d para el tratamiento de trastornos neurodegenarativos.
CO2018000809A2 (es) Anticuerpos para cd40
PH12015502075A1 (en) Treatment of cataplexy
MX2015011670A (es) Tratamiento y prevencion de lesion renal aguda usando anticuerpos anti-alfa v beta 5.
AR101740A1 (es) Terapia de combinación y composiciones
EA201690728A1 (ru) Применение молекул, связывающих семафорин-4d, для лечения атеросклероза
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
MX376008B (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MX2015011772A (es) Anticuerpos anti-hepcidina y usos de los mismos.
EA201591786A1 (ru) Монотерапия gla для применения в лечении рака
MX377190B (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
MX377089B (es) Uso de una proteína angiopoyetina modificada en la preparación de un medicamento para prevenir o tratar la malaria cerebral.
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
MX385854B (es) Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos.
MX366046B (es) Moléculas de unión que se adhieren al factor de complemento c2 humano y usos de los mismos.
MX383323B (es) Grelina para uso en el tratamiento de lesión del cerebro traumática leve.
CR20150496A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
EA201791365A1 (ru) Замещенный пиридил-циклоалкил-карбоновые кислоты, содержащие их композиции и их медицинское применение
BR112015023463A2 (pt) uso de sedoeptulose para prevenção ou tratamento de inflamação
CL2016000951A1 (es) Forma cristalina anhidra h de cabazitaxel; proceso de preparación; composición farmacéutica que la comprende; útil para tratar cáncer.